PRODUCTION OF THE IMMUNOTOXIN IGY ANTI CD133 COUPLED TO AN ABRIN FOR TREATING TUMORS IN THE CENTRAL NERVOUS SYSTEM AND/OR NEOPLASMS RELATED TO CARCINOGENIC STEM CELLS.
BENJAMÍN PINEDA OLVERA,EDGAR RANGEL LÓPEZ,VERÓNICA PÉREZ DE LA CRUZ,NORMA YANET HERNÁNDEZ PEDRO
申请号：
MX2015004554
公开号：
MX2015004554A
申请日:
2015.04.10
申请国别(地区):
MX
年份:
2015
代理人:
摘要：
The carcinogenic stem cells have self-renovation and resistance characteristics to radio and chemotherapy. Antigen CD133 allows carcinogenic stem cells to be identified in osteosarcoma, melanoma, breast cancer, prostate tumors, retinoblastoma, leukemia, non small cell lung cancer, tumors in the central nervous system and larynx and hepatocellular carcinoma. Malignant gliomas represent 70% of the malignant brain tumors. The survival of these patients is poor despite the current treatments. Abrin specifically and irreversibly inhibits the protein synthesis of eukaryotic cells. The advantage of producing an anti CD133 coupled to an abrin is that drugs are selectively released to tumors, reducing toxicity and increasing their power. The present application includes the description and technical data for the production of an immunotoxin of the lgY type coupled to the A chain of the abrin toxin, using techniques of recombinant DNA for the production of the AC133 antigen and the A chain of a brin. This project offers an alternative for eradicating carcinogenic stem cells for developing a specific and affordable therapy that help or replace current therapies, providing a better life quality and expectancy to patients with cancer.Las células madre carcinogénicas presentan características de auto renovación y resistencia a radio y quimioterapia. El antígeno CD133 permite identificar células madre carcinogénicas en osteosarcomas, melanomas, cáncer de mama, tumores prostáticos, retinoblastomas, leucemias, cáncer de pulmón de células no pequeñas, tumores del Sistema Nervioso Central y carcinomas de laringe y hepatocelulares. Los gliomas malignos representan el 70% de los tumores cerebrales malignos. La sobrevida de estos pacientes es pobre a pesar de los tratamientos actuales. La Abrina inhibe específica e irreversiblemente la síntesis proteica de células eucariotas. La ventaja de producir un anti CD133 acoplado a abrina es liberar selectivamente fármacos a los tumores, reducien
